复发转移性结直肠癌的化疗进展

《复发转移性结直肠癌的化疗进展》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、2006’亚太地区肿瘤生物学和医学会议thesesamplesweredetectedbyIHC．ThedatashowedthatHer-2overexpressionratewas23．4％，andHer-2overexpressionwererelatedwithlargersize，morelymphnodepositive，andERnegative，PRnegativeandP53positive．Her-2overexpressionpatientsshowedshortdiseasefreesurvival，meansHer-2wasapr

2、ognosisfactorforearlystagebreastcancer．MultivariateanalysisshowedthatoverexpressionofHer-2togetherwithlaterstage，largerprimarytumorside，andlymphnodepositiveandERnegativewasrelatedwithpoorprognosis．Ourstudyisoneofthelargestsamplesizesabouther-2expressioninChinesewomenwithbreastcanc

3、er．Furtherstudy，weanalyzethepredictiveeffectofHer-2fortheclinicalsensitivityoftaxaneinadvancedbreastcancerinthisretrospectiveclinicpathologicstudy．268patientswithadvancedbreastcancer,ofwhich71patientswerepaclitaxelusedasasingleagent，and32patientsweredocetaxelalone，110patientsofpac

4、litaxelwereadministeredincombinationwithanthracylines，gemcitabine，andplatins．55patientsweredocetaxelcombinations．Inunivariateanalysis，theresponserate(RR)inHer-2overexpressionalTflandHer-2lower-expressionarlnwere56．7％，and33．3％，respectively，thedifferencewassignificant(p=0．003)．Meanw

5、hile，inERnegativealTtlandHer-2overexpressionarm，theRRwere67．6％，higherthanHer-2overexpressionERpositivealTnandHer-2lower-expressionandERpositive／negativealmsfP<0．01)．MultivariateanalysisshowedthatoverexpressionofHer-2hadsignificantdifference(p=0．007)．OurstudiessuggestedthatHer-2ove

6、rexpressionwerepredictivegoodresponsetotaxaneschemotherapyinpatientswithadvancedbreastcancer．Keywords=Breastcancer；humanepidermalgrowthfactorreceptor2(Her-2)；prognosisfactor；Taxanes；chemosensitivity复发转移性结直肠癌的化疗进展李进(上海复旦大学肿瘤医院化疗科，上海，200032)擅要：结直肠癌是消化系统的高发恶性肿瘤之一。复发转移性结直肠癌的五年生存率只有5．8

7、％。目前主要的治疗手段仍是化疗，本文就在5-FU基础上加用细胞毒药物疗法的临床应用和分子靶向药物的开发对近年来复发转移性结直肠癌化疗的相关进展作一综述。ProgressofChemotherapyoftheMetastaticandRecurrentColorectalCancer492006’亚太地区肿瘤生物学和医学会议JinLiDepartmentofChemotherapy，CancerHospital，FudanUniversity,Shanghai200032，ChinaAbstract：Thecolorectalcancerisoneofhig

8、hlymorbidityofmalignancycarcinoma